This is the largest Covid-19 vaccine deal that the US government has yet concluded, bypassing last week’s $ 1.95 billion agreement for 100 million doses of the Pfizer and BioNTech vaccine, according to Forbes.
This is the sixth candidate vaccine to join the Warp Speed process portfolio, and the largest vaccine deal to date.
The U.S. federal government had previously entered into similar deals with AstraZeneca, Johnson & Johnson, Moderna and Novavax as well as Pfizer.
Funds will go toward clinical trials, increased manufacturing and 100 million doses of vaccine.
“The group of vaccines that are being collected raises the possibility that we will have at least one safe and effective vaccine at the end of this year,” said Alex Azar, US Secretary of Health and Human Services, in a statement announcing the deal.
However, the candidate “GSK-Sanofi” vaccine did not go far in the search for a vaccine for the Coronavirus, as reported by American media.
While some candidate vaccines reached the third stage of clinical trials.
To date, the GSK-sanofi vaccine has only been studied in preclinical trials.
Human studies for the vaccine are expected to begin next September.
And if the data show that the vaccine is safe and effective, companies can request the approval of the US Food and Drug Administration sometime in the first half of 2021.